A lung-targeting green biomimetic gold nanoparticle, its preparation method and application

By preparing lung-targeting biomimetic gold nanoparticles loaded with the active ingredient of Platycodon grandiflorus, and by coating the gold nanoparticles with macrophage membranes, the problems of systemic distribution and adverse reactions of existing anti-inflammatory drugs were solved, achieving targeted lung inflammation and long-term circulation, thus enhancing the anti-inflammatory effect.

CN123059019APending Publication Date: 2026-11-10ANHUI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611330905.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-08-31
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing anti-inflammatory drugs for the treatment of pneumonia patients have problems such as rapid metabolism, non-selective systemic distribution, and serious adverse reactions. In addition, the bioavailability of the active ingredient of Platycodon grandiflorus is low, and there is a lack of targeted delivery technology.

Method used

Lung-targeting biomimetic gold nanoparticles loaded with the active ingredient of Platycodon grandiflorus were prepared using self-assembly technology. The gold nanoparticles were then coated with macrophage membranes, combining the theory of meridian guidance in traditional Chinese medicine with modern targeted delivery to achieve lung inflammation targeting and immune evasion.

Benefits of technology

It improves the bioavailability of the active ingredients of Platycodon grandiflorus, reduces adverse reactions of systemic immunosuppression, achieves targeted delivery and long circulation in the inflammatory area of ​​the lungs, and has pharmacological effects such as anti-inflammatory and antioxidant effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123059019A_ABST
    Figure CN123059019A_ABST
Patent Text Reader

Abstract

This invention belongs to the field of pharmaceutical technology, specifically relating to a lung-targeting green biomimetic gold nanoparticle, its preparation method, and its application. This invention utilizes Platycodon grandiflorus extract (PGE) to reduce tetrachloroauric acid trihydrate, self-assembling to form gold nanoparticles (PGE-AuNPs), which are then coated with macrophage membranes to obtain a biomimetic nanosystem (MM@PGE-AuNPs). This system can actively target inflamed areas, evade clearance by the reticuloendothelial system, prolong in vivo circulation time, improve the bioavailability of Platycodon grandiflorus' active ingredients, and enhance its anti-inflammatory effects. This invention combines traditional Chinese medicine meridian theory with modern targeted delivery concepts. The preparation process is green and simple, and it can be used to prepare drugs for treating inflammatory lung diseases such as pneumonia, acute lung injury, and acute respiratory distress syndrome.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of medical technology, specifically relating to a lung-targeting biomimetic gold nanoparticle, its preparation method, and its application. Background Technology

[0002] Pneumonia is an acute respiratory infection affecting the lungs, caused by bacteria, viruses, or other pathogens. It can rapidly lead to acute lung injury and acute respiratory distress syndrome, and is one of the leading causes of death from infection worldwide.

[0003] Currently, anti-inflammatory drugs for pneumonia mainly include selective cytokine blockers targeting interleukin-1 and tumor necrosis factor-α, as well as broad-spectrum hormonal immunosuppressants. The effectiveness of these drugs in controlling pneumonia has been validated in clinical treatment. However, these drugs generally suffer from rapid metabolism and non-selective systemic distribution, requiring frequent high-dose administration to effectively suppress the immune response. Extensive systemic immunosuppression is often accompanied by severe adverse reactions and sequelae, such as femoral head necrosis, significantly impacting patients' post-treatment quality of life. Therefore, there is an urgent need to develop a drug that can target the inflammatory area while having fewer side effects.

[0004] Platycodon grandiflorus has expectorant and antitussive effects. Modern research shows that it contains various reducing substances and possesses pharmacological effects such as anti-inflammatory, antibacterial, antitumor, antioxidant, and immunomodulatory properties. Traditional Chinese medicine has long considered Platycodon grandiflorus to be the "boat and oar" of the lungs, making it the first choice for "guiding and delivering" the lung meridian, which aligns with the guiding principles of modern targeted delivery. However, the low bioavailability of some active ingredients in Platycodon grandiflorus limits its full therapeutic effect.

[0005] Gold nanoparticles have attracted widespread attention due to their low toxicity and excellent biocompatibility. Plant-mediated green synthesis of gold nanoparticles not only exhibits low toxicity but also plays a crucial role in immune regulation. Nanoparticles coated with macrophage membranes can actively target inflammatory sites, effectively evading clearance by the reticuloendothelial system and prolonging their circulation time in vivo. However, a technical solution that organically combines the Platycodon grandiflorus meridian-guided theory, green synthesis of gold nanoparticles, and macrophage membrane coating is currently lacking. Summary of the Invention

[0006] One objective of this invention is to provide lung-targeting biomimetic gold nanoparticles loaded with the active ingredient of Platycodon grandiflorus (PG). Specifically, it is a biomimetic nanosystem of green gold nanoparticles formed by the self-assembly of Platycodon grandiflorus extract (PGE) coated on a macrophage membrane and tetrachloroauric acid trihydrate (HAuCl4·3H2O). This biomimetic nanosystem has the function of targeting inflamed areas.

[0007] To achieve the above objectives, the present invention employs the following technical solution: a lung-targeting green biomimetic gold nanoparticle, comprising; The gold nanoparticle core is formed by the self-assembly of Platycodon grandiflorus extract (PGE) and tetrachloroauric acid trihydrate (HAuCl4·3H2O); And the macrophage membrane that coats the core of the gold nanoparticles.

[0008] A second objective of this invention is to provide a method for preparing the above-mentioned lung-targeting green biomimetic gold nanoparticles, comprising the following steps: S1. Platycodon grandiflorum extract was mixed with tetrachloroauric acid trihydrate and then heated to react and self-assemble to form PGE-AuNPs; S2. Extract macrophage membranes; S3. The macrophage membrane is mixed with the PGE-AuNPs and subjected to ultrasonic and extrusion treatment to coat the surface of the PGE-AuNPs with the macrophage membrane, thus obtaining MM@PGE-AuNPs.

[0009] A further technical solution for the preparation method of the above-mentioned lung-targeting green biomimetic gold nanoparticles: Preferably, step S1 is as follows: Platycodon grandiflorus extract is prepared into a PGE solution with a concentration of 12-16 mg / ml, and mixed with a HAuCl4·3H2O solution with a concentration of 100 mM at a volume ratio of 1:1. The mixture is heated at 60-70℃ for 40 min, and after centrifugation, washing, and resuspending, PGE-AuNPs are obtained.

[0010] Preferably, the macrophage membrane in step S2 is derived from macrophages and is extracted by a combination of hypotonic incubation and mechanical extrusion.

[0011] Preferably, the preparation steps of the macrophage membrane in step S2 are as follows: After collecting macrophages, dilute them with TM buffer containing 1% PMSF to a concentration of 2.5 × 10⁻⁶. 7 The cells were incubated overnight in a hypotonic atmosphere at a concentration of 1 cell / mL. The cell structure was mechanically destroyed using a liposome extruder, and the cell homogenate was collected. Sucrose solution was added to a final concentration of 0.25 M, and the cells were centrifuged sequentially at relative centrifugal forces of 2000-3000 g and 2000-3000 g. The precipitate was collected to obtain the macrophage membrane.

[0012] Preferably, in step S3, the mass ratio of the macrophage membrane to the PGE-AuNPs is 1:2.

[0013] Preferably, in step S3, the ultrasonic treatment time is 3-5 min, and the extrusion process passes through 400 nm and 200 nm polycarbonate films in sequence.

[0014] The third objective of this invention is to provide an application of the above-mentioned lung-targeting green biomimetic gold nanoparticles in the preparation of drugs for treating inflammatory lung diseases.

[0015] Further technical solutions for the application of the aforementioned lung-targeting green biomimetic gold nanoparticles in the preparation of drugs for treating inflammatory lung diseases: Preferably, the inflammatory lung diseases include pneumonia, acute lung injury (ALI), and / or acute respiratory distress syndrome (ARDS).

[0016] Preferably, the gold nanoparticles have the ability to target inflammatory areas and evade clearance by the reticuloendothelial system through macrophage membrane coating.

[0017] The advantages of this invention compared to the prior art are as follows: 1. This invention provides lung-targeting green biomimetic gold nanoparticles (MM@PGE-AuNPs), whose structure consists of a gold nanoparticle core formed by the self-assembly of Platycodon grandiflorum extract (PGE) and tetrachloroauric acid trihydrate, and a macrophage membrane shell encapsulating the core. In this structure, Platycodon grandiflorum extract participates in the construction of gold nanoparticles as both a reducing agent and an active ingredient, avoiding the use of toxic reagents in traditional chemical synthesis and anchoring the active ingredient of Platycodon grandiflorum in situ on the surface of the nanoparticles, thereby improving its bioavailability and promoting its anti-inflammatory, antibacterial, and antioxidant pharmacological effects. The macrophage membrane shell endows the nanoparticles with the ability to actively target inflamed areas, and can also act as a "self" recognition signal to block the exposure of exogenous substances, evade the uptake and clearance of the reticuloendothelial system (RES), prolong the in vivo circulation time, and reduce adverse reactions caused by systemic immunosuppression. This invention combines the traditional Chinese medicine theory of "Platycodon grandiflorum as the boat and oar of the lung" with the modern targeted delivery concept, realizing the organic integration of traditional Chinese medicine theory and nanotechnology.

[0018] 2. This invention provides a method for preparing MM@PGE-AuNPs, utilizing the natural reducing substances in Platycodon grandiflorus extract to reduce Au... 3+ Restore to Au 0 Platycodon grandiflorus extract serves as both a reducing agent and an active ingredient, eliminating the need for exogenous chemical reducing agents. The preparation process is green and environmentally friendly, avoiding the biotoxicity of residual chemical reagents; the synthesis conditions are mild (70℃, normal pressure), with low energy consumption, simple operation, and easy scale-up; the active ingredient of Platycodon grandiflorus is loaded in situ on the surface of gold nanoparticles, avoiding drug loss and activity reduction in traditional drug loading processes.

[0019] In the macrophage membrane extraction process, a combination of hypotonic incubation and mechanical extrusion is used. This gentle operation avoids the damage to membrane protein structure and biological activity caused by high-intensity treatments such as ultrasonic disruption, thus preserving the natural conformation and recognition function of inflammation-targeting receptors on the macrophage membrane surface. Combined with differential centrifugation and sucrose density adjustment, the cell nucleus and other organelles can be efficiently removed to obtain high-purity cell membranes.

[0020] In the MM@PGE-AuNPs assembly process, ultrasonic treatment ensures full contact between membrane fragments and nanoparticles. Then, gradient extrusion of 400 nm and 200 nm polycarbonate membranes precisely controls the particle size distribution of the coated nanoparticles, resulting in a uniform final product. The co-extrusion method maintains the natural orientation of the membrane proteins, ensuring the recognition ability of inflammatory chemokines. The complete and continuous shell structure effectively shields the exogenous epitopes of the core, giving the nanoparticles "stealth" properties and providing a structural basis for them to evade RES clearance and achieve long-term circulation.

[0021] In summary, through optimized design of each preparation step, this invention has obtained a well-defined and functionally integrated MM@PGE-AuNPs biomimetic nanosystem, which has multiple beneficial effects such as being green and safe, targeting lung inflammation, facilitating immune escape and long-term circulation, and enhancing anti-inflammatory effects. Attached Figure Description

[0022] Figure 1 Flowchart of the preparation process of MM@PGE-AuNPs of this invention.

[0023] Figure 2 The middle part is the optimization of the conditions for preparing PGE-AuNPs from raw material PGE and step S1 of Example 1.

[0024] Figure 3 The images show the raw material PGE, the PGE-AuNPs obtained in step S1 of Example 1, and the MM@PGE-AuNPs synthesized in step S3 of Example 1.

[0025] Figure 4 These are TEM images of PGE-AuNPs obtained in step S1 of Example 1 and MM@PGE-AuNPs synthesized in step S3 of Example 1.

[0026] Figure 5 The changes in size and Zete potential of the PGE-AuNPs obtained in step S1 of Example 1 and the MM@PGE-AuNPs synthesized in step S3 of Example 1 are shown.

[0027] Figure 6 The four-week stability changes of PGE-AuNPs obtained in step S1 of Example 1 and MM@PGE-AuNPs synthesized in step S3 of Example 1 are shown.

[0028] Figure 7 The changes in infrared absorption peaks of PGE and PGE-AuNPs obtained in step S1 of Example 1, and the active ingredients loaded on PGE-AuNPs.

[0029] Figure 8 The experiment involved cellular uptake of raw material PGE, PGE-AuNPs obtained in step S1 of Example 1, and MM@PGE-AuNPs synthesized in step S3 of Example 1.

[0030] Figure 9 The anti-inflammatory activity of the raw material PGE, the PGE-AuNPs prepared in step S1 of Example 1, and the MM@PGE-AuNPs synthesized in step S3 of Example 1 was detected.

[0031] Figure 10 The ROS detection results were obtained from raw material PGE, PGE-AuNPs prepared in step S1 of Example 1, and MM@PGE-AuNPs synthesized in step S3 of Example 1.

[0032] Figure 11 The study included the detection of ATP-related genes and their contents in raw material PGE, PGE-AuNPs obtained in step S1 of Example 1, and MM@PGE-AuNPs synthesized in step S3 of Example 1.

[0033] Figure 12 It refers to the in vivo uptake of raw material PGE, PGE-AuNPs obtained in step S1 of Example 1, and MM@PGE-AuNPs synthesized in step S3 of Example 1.

[0034] Figure 13 HE staining of raw material PGE, PGE-AuNPs obtained in step S1 of Example 1, and MM@PGE-AuNPs synthesized in step S3 of Example 1.

[0035] Figure 14 The in vivo anti-inflammatory effects of raw material PGE, PGE-AuNPs obtained in step S1 of Example 1, and MM@PGE-AuNPs synthesized in step S3 of Example 1 are compared.

[0036] Figure 15 The in vitro hemolysis and in vivo safety of the raw material PGE, the PGE-AuNPs prepared in step S1 of Example 1, and the MM@PGE-AuNPs synthesized in step S3 of Example 1. Detailed Implementation

[0037] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be further described in detail below with reference to the embodiments. All other embodiments obtained by those skilled in the art based on the embodiments of this invention without creative effort are within the scope of protection of this invention.

[0038] Example 1

[0039] This invention provides a method for preparing MM@PGE-AuNPs, the process of which is as follows: Figure 1 As shown, the specific steps include the following: Synthesis of S1 and PGE: PG powder was mixed with 70% ethanol at a solid-liquid ratio of 1:8 (g / mL), and then soaked for 30-50 minutes. The mixture was then refluxed in a 70°C water bath for 1 hour, and filtered immediately after extraction. The reflux filtration procedure was repeated three times. All filtrates were combined and centrifuged to collect the supernatant. The supernatant was then concentrated to 50 mL and freeze-dried to obtain PGE.

[0040] Synthesis of PGE-AuNPs: Weigh 0.5 g of Platycodon grandiflorus extract (PGE) and add pure water to prepare a stock solution with a concentration of 50 mg / ml. Filter the supernatant through a 0.22 µm filter at 5000 rpm for 15 min. Simultaneously, prepare a stock solution of 100 mM HAuCl4·3H2O. Add 280 μL of the PGE stock solution to 720 μL of pure water to prepare a 1 ml PGE solution with a concentration of 14 mg / ml. After mixing, discard 10 μL of the solution and add 10 μL of the HAuCl4·3H2O stock solution. Mix well and heat at 70 °C for 40 min; a deep purple color will be observed. Centrifuge at 4 °C and 12000 rpm for 30 min, discard the supernatant, and resuspend the precipitate in 1 ml of pure water. Repeat the centrifugation and resuspension under the same conditions.

[0041] Extraction of macrophage membranes: When macrophages reached 80% confluence, the old culture medium was aspirated, and fresh culture medium was added. Cells were scraped off with a cell scraper and collected into 50 ml centrifuge tubes. The cell concentration was calculated using a cell counter. The cells were centrifuged at 1300 rpm for 5 min, and the supernatant was discarded. The collected cell pellet was placed on ice and diluted to 2.5 × 10⁻⁶ with TM buffer containing 1% PMSF. 7The cells were incubated overnight at a concentration of 1 cell / mL under hypotonic conditions. The collected cell suspension was squeezed 25 times using a liposome extractor without a polycarbonate membrane to mechanically disrupt cell structure and obtain a cell homogenate. 1 M sucrose solution was added to the homogenate to a final concentration of 0.25 M. The homogenate was centrifuged at 4°C and 2000 g for 15 min, the precipitate was discarded, and the supernatant was collected. This centrifugation was repeated once to discard any remaining nuclei, organelles, and other structures. The collected supernatant was centrifuged at 4°C and 3000 g for 30 min, and the precipitate was collected as the macrophage membrane. The macrophage membrane was stored at 80°C for later use.

[0042] Synthesis of MM@PGE-AuNPs: The prepared macrophage membrane was centrifuged at 3000g for 30 min at 4℃ to collect the further purified macrophage membrane. The supernatant was discarded and the membrane was resuspended in 1 ml of pure water. The macrophage membrane and PGE-AuNPs were mixed evenly at a mass ratio of 1:2. After sonication for 5 min, the membrane was co-extruded sequentially through 400 nm and 200 nm polycarbonate membranes in a liposome extruder, and extruded back and forth 15 times. The membrane was then stored at 4℃.

[0043] Performance testing: Figure 1 This is a flowchart of the preparation process of MM@PGE-AuNPs. First, PGE-AuNPs are synthesized through PGE, and then they are repeatedly physically extruded with cell membranes extracted from macrophages through a lipid extruder.

[0044] Figure 2 The optimization of the conditions for preparing PGE-AuNPs from the raw material PGE and step S1 of Example 1 was achieved by optimizing the extract concentration, reaction time, HAuCl4·3H2O concentration and reaction temperature to obtain the optimal synthesis conditions, namely the steps of Example 1.

[0045] Figure 3 The images show the raw material PGE, the PGE-AuNPs prepared in step S1 of Example 1, and the MM@PGE-AuNPs synthesized in step S3 of Example 1. The Tyndall effect indicates the presence of nanoparticles in the liquid.

[0046] Figure 4 These are TEM images of PGE-AuNPs obtained in step S1 of Example 1 and MM@PGE-AuNPs synthesized in step S3 of Example 1, showing the morphology and size of the nanoparticles.

[0047] Figure 5 This refers to the size and Zete potential changes of the PGE-AuNPs obtained in step S1 of Example 1 and the MM@PGE-AuNPs synthesized in step S3 of Example 1. Specifically, 1 mL of liquid was analyzed using a particle size analyzer. Figure 5The test results show the hydrodynamic particle size and stability of PGE-AuNPs and MM@PGE-AuNPs.

[0048] Figure 6 This describes the four-week stability changes of the PGE-AuNPs obtained in step S1 of Example 1 and the MM@PGE-AuNPs synthesized in step S3 of Example 1. Specifically, the PGE-AuNPs and MM@PGE-AuNPs liquids were subjected to UV detection to monitor the changes in absorption peaks over four weeks. Figure 6 The test results show that PGE-AuNPs and MM@PGE-AuNPs are stable.

[0049] Figure 7 This describes the changes in the infrared absorption peaks of PGE and the PGE-AuNPs prepared in step S1 of Example 1, as well as the active components loaded onto the PGE-AuNPs. Specifically, potassium bromide and the sample were uniformly ground at a ratio of 100:5 to prepare thin slices, which were then detected by Fourier transform infrared spectroscopy and ultra-high performance liquid chromatography-high resolution tandem mass spectrometry (UHPLC-MS / MS) to detect the 70% ethanol dissociation components of the PGE-AuNPs. Figure 7 The test results show that PGE-AuNPs are loaded with multiple active ingredients of PGE.

[0050] Figure 8 This study describes the cellular uptake experiments of raw material PGE, PGE-AuNPs prepared in step S1 of Example 1, and MM@PGE-AuNPs synthesized in step S3 of Example 1. Specifically, RAW264.7 macrophages and GES-1 cells were cultured in 12-well plates for 24 hours. The next day, the original culture medium was replaced with fresh PGE-AuNPs@C6 or MM@PGE-AuNPs@C6 containing any of the following components. After culturing for 1–4 hours, the cells were washed three times with phosphate-buffered saline (PBS), fixed with 4% formaldehyde for 15 minutes, and washed again with PBS. After the final PBS wash, cell uptake was observed under a microscope. To simulate an inflammatory cell model, PGE-AuNPs C6 or MM@PGE-AuNPs@C6 was mixed with 1 μg / mL of lipopolysaccharide (LPS) and then administered. Subsequently, the ability to target inflammatory cells was observed and evaluated. The results were then obtained by testing. Figure 8 It is known that MM@PGE-AuNPs@C6 has better immune escape and targeting of inflammatory areas.

[0051] Figure 9This study describes the detection of NO in PGE, PGE-AuNPs obtained in step S1 of Example 1, MMs extracted in step S2 of Example 1, a simple mixture of PGE-AuNPs obtained in step S1 of Example 1 and MMs extracted in step S2 of Example 1, and MM@PGE-AuNPs synthesized in step S3 of Example 1. The specific steps involve collecting RAW264.7 cell culture medium and performing different treatments. Different groups of drugs are mixed with lipopolysaccharide (LPS) and then administered. After incubation for 24 hours, the supernatant is mixed with NO detection reagent at a 1:1 ratio, incubated in an incubator for 30 minutes, and detected at 570 OD. Figure 9 The test results show that MM@PGE-AuNPs have good anti-inflammatory activity.

[0052] Figure 10 This study describes the ROS detection of raw material PGE, PGE-AuNPs prepared in step S1 of Example 1, and MM@PGE-AuNPs synthesized in step S3 of Example 1. The specific steps are as follows: RAW264.7 cells were incubated in 6-well plates for 24 hours. Cells were randomly divided into five groups: control group, LPS model group, PGE group, PGE-AuNPs group, and MM@PGE-AuNPs group. Except for the control group, cells in all other groups were treated with 1 mg / mL LPS to establish an inflammation model. After incubation, cells were washed with sterile PBS and then incubated with a DCFH-DA fluorescent probe at 37°C for 30 minutes to label intracellular ROS. The ROS were observed under a fluorescence inverted microscope. Figure 10 The test results show that MM@PGE-AuNPs have good resistance to ROS generation.

[0053] Figure 11 This study investigated the ATP-related genes and their contents in raw material PGE, PGE-AuNPs prepared in step S1 of Example 1, and MM@PGE-AuNPs synthesized in step S3 of Example 1. The specific steps involved incubating RAW264.7 cells in 6-well plates for 24 hours. Cells were randomly divided into five groups: control group, LPS model group, PGE group, PGE-AuNPs group, and MM@PGE-AuNPs group. Except for the control group, all other groups were treated with 1 mg / mL LPS to establish an inflammation model. After incubation, cells were washed with sterile PBS, and then mRNA and ATP were extracted for detection. Figure 10 The test results show that MM@PGE-AuNPs promote ATP production.

[0054] Figure 12This refers to the in vivo uptake of raw material PGE, PGE-AuNPs prepared in step S1 of Example 1, and MM@PGE-AuNPs synthesized in step S3 of Example 1. Specifically, after establishing an ALI mouse model, mice were randomly divided into two groups, and PGE-AuNPs@Cy5.5 and MM@PGE-AuNPs@Cy5.5 were intravenously injected. Whole-body fluorescence imaging was performed at different time points using an in vivo imaging system (IVIS). Twenty-four hours after administration, the mice were euthanized, and the major organs (heart, liver, spleen, lungs, and kidneys) were rapidly isolated. Then, in vitro fluorescence imaging was performed on the isolated organs to qualitatively analyze the distribution and enrichment of the labeled nanoparticles in various tissues. Figure 12 The test results show that MM@PGE-AuNPs have a better ability to target and enrich inflammatory organs.

[0055] Figure 13 HE staining was performed on the raw material PGE, PGE-AuNPs prepared in step S1 of Example 1, and MM@PGE-AuNPs synthesized in step S3 of Example 1. Mouse lung tissue was collected, washed with PBS to remove residual blood, and then fixed with 4% paraformaldehyde (PFA) at 4°C for 24 hours. Paraffin embedding and sectioning were then performed according to standard laboratory procedures. The paraffin sections were then stained with hematoxylin and eosin according to standard protocols. After staining, the sections were observed and imaged using an inverted microscope to assess histopathological changes. Figure 13 The test results show that MM@PGE-AuNPs have a good ability to repair tissue damage in vivo and in vitro.

[0056] Figure 14 This study investigated the in vivo anti-inflammatory effects of raw material PGE, PGE-AuNPs prepared in step S1 of Example 1, and MM@PGE-AuNPs synthesized in step S3 of Example 1. Specifically, the levels of inflammatory factors (IL-6, TNF-α, IL-1β) in mouse serum and lung tissue were measured using an enzyme-linked immunosorbent assay (ELISA) kit. Figure 14 The test results show that MM@PGE-AuNPs have better anti-inflammatory capabilities.

[0057] Figure 15This study investigated the in vitro hemolysis and in vivo safety of the raw material PGE, PGE-AuNPs prepared in step S1 of Example 1, and MM@PGE-AuNPs synthesized in step S3 of Example 1. Specifically, RAW264.7 macrophages were cultured in 96-well plates for 24 hours. Subsequently, PGE, PGE-AuNPs, and MM@PGE-AuNPs were incubated at the same concentration for 24 hours. MTT solution was added to each well, followed by a further 4-hour incubation. The supernatant was discarded, and dimethyl sulfoxide (DMSO) was added to each well. Finally, the optical density (OD) at 595 nm was measured using a microplate reader to assess cell viability. Mouse red blood cells (RBCs) were collected from retro-orbital venous blood and used to prepare a 2% (v / v) red blood cell suspension. Then, 0.5 mL of RBC suspension was mixed with an equal volume (0.5 mL) of physiological saline (negative control), distilled water (positive control), PGE solution, PGE-AuNPs solution, and MM@PGE-AuNPs solution. All mixtures were incubated at 37°C for 2 hours, followed by centrifugation at 3000×g for 10 minutes at 4°C to collect the supernatant. The absorbance of the supernatant at 570 nm was measured to quantify the hemoglobin released from hemolyzed erythrocytes. Mouse liver, heart, spleen, lung, and kidney tissues were collected, washed with PBS to remove residual blood, and then fixed with 4% paraformaldehyde (PFA) at 4°C for 24 hours. Paraffin embedding and sectioning were then performed according to standard laboratory procedures. The paraffin sections were then stained with hematoxylin and eosin according to standard protocols. After staining, the sections were observed and imaged using an inverted microscope to assess the histopathological changes of the tissues. Figure 15 The test results show that MM@PGE-AuNPs have good biocompatibility in vivo and in vitro.

[0058] Those skilled in the art should understand that the above descriptions are merely several specific embodiments of the present invention, and not all embodiments. It should be noted that many modifications and improvements can be made by those skilled in the art, and all modifications or improvements not exceeding the scope of the claims should be considered within the protection scope of the present invention.

Claims

1. A lung-targeting green biomimetic gold nanoparticle, characterized in that, include: The gold nanoparticle core is formed by the self-assembly of Platycodon grandiflorus extract PGE and tetrachloroauric acid trihydrate HAuCl4·3H2O. And the macrophage membrane that coats the core of the gold nanoparticles.

2. A method for preparing lung-targeting green biomimetic gold nanoparticles as described in claim 1, characterized in that, Includes the following steps: S1. Platycodon grandiflorus extract is mixed with tetrachloroauric acid trihydrate and then subjected to a reduction reaction under heating to form PGE-AuNPs; S2. Extract macrophage cell membranes; S3. The macrophage membrane is mixed with the PGE-AuNPs and subjected to ultrasonic and extrusion treatment to coat the surface of the PGE-AuNPs with the macrophage membrane, thus obtaining MM@PGE-AuNPs; Steps S1 and S2 are not in any particular order.

3. The method for preparing lung-targeted green biomimetic gold nanoparticles according to claim 2, characterized in that, Step S1 is as follows: Prepare a PGE solution with a concentration of 12-16 mg / ml by preparing Platycodon grandiflorus extract, mix it with a 100 mM HAuCl4·3H2O solution at a volume ratio of 1:1, heat at 60-70℃ for 40 min, and obtain PGE-AuNPs after centrifugation, washing and resuspending.

4. The method for preparing lung-targeted green biomimetic gold nanoparticles according to claim 2, characterized in that, The macrophage membrane mentioned in step S2 is derived from macrophages and is extracted by a combination of hypotonic incubation and mechanical extrusion.

5. The method for preparing lung-targeted green biomimetic gold nanoparticles according to claim 2 or 4, characterized in that, The preparation steps of the macrophage membrane in step S2 are as follows: After collecting macrophages, dilute them with TM buffer containing 1% PMSF to a concentration of 2.5 × 10⁻⁶. 7 The cells were incubated overnight in a hypotonic atmosphere at a concentration of 1 cell / mL. The cell structure was mechanically destroyed using a liposome extruder, and the cell homogenate was collected. Sucrose solution was added to a final concentration of 0.25 M, and the cells were centrifuged sequentially at relative centrifugal forces of 2000-3000 g and 2000-3000 g. The precipitate was collected to obtain the macrophage membrane.

6. The method for preparing lung-targeted green biomimetic gold nanoparticles according to claim 2, characterized in that, In step S3, the mass ratio of the macrophage membrane to the PGE-AuNPs is 1:

2.

7. The method for preparing lung-targeted green biomimetic gold nanoparticles according to claim 2, characterized in that, In step S3, the ultrasonic treatment time is 3-5 min, and the extrusion process is carried out sequentially through 400 nm and 200 nm polycarbonate films.

8. The use of the lung-targeting green biomimetic gold nanoparticles of claim 1 in the preparation of drugs for treating inflammatory lung diseases.

9. The application of the lung-targeting green biomimetic gold nanoparticles according to claim 8 in the preparation of drugs for treating inflammatory lung diseases, characterized in that, The inflammatory lung diseases mentioned include pneumonia, acute lung injury (ALI), and / or acute respiratory distress syndrome (ARDS).

10. The application of the lung-targeting green biomimetic gold nanoparticles according to claim 8 in the preparation of drugs for treating inflammatory lung diseases, characterized in that, The gold nanoparticles have the ability to target inflammatory areas and evade clearance by the reticuloendothelial system through macrophage membrane coating.